Rocuronium bromide is a non-depolarizing neuromuscular blocking agent (NMBA) of the aminosteroid class. It acts as a competitive antagonist at the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction, leading to skeletal muscle relaxation and paralysis. It is primarily used as an adjunct to general anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgical procedures. Its intermediate duration of action and rapid onset, especially at higher doses, make it a widely used agent in operating rooms and intensive care units across India.
Adult: For intubation: 0.6 mg/kg IV bolus. For maintenance: 0.15 mg/kg IV bolus or 0.3-0.6 mg/kg/hr IV infusion. For RSI: 0.9-1.2 mg/kg IV bolus. Dose must be individualized based on patient factors and anesthetic regimen.
Note: For IV use only. Must be administered as a bolus injection into a secure intravenous line. Should be given after the patient is unconscious (induction of anesthesia). Compatible with common IV fluids (NS, D5W). Do not mix in the same syringe with alkaline solutions (e.g., barbiturates like thiopental) as precipitation may occur. Neuromuscular monitoring (Train-of-Four) is ESSENTIAL.
Rocuronium is a competitive antagonist of acetylcholine at the post-synaptic nicotinic receptors of the neuromuscular junction. It binds to the alpha-subunit of the receptor but does not activate it, preventing the depolarization of the motor endplate. This inhibition of neuromuscular transmission results in flaccid paralysis of skeletal muscles, proceeding in a characteristic sequence: eyelids and jaw muscles first, followed by limbs, abdomen, and diaphragm. Intercostal muscles are paralyzed before the diaphragm.
Pregnancy: Category B: No well-controlled studies in pregnant women. Should be used during pregnancy only if clearly needed. Crosses the placenta in small amounts, especially with high/repeated doses. May cause neonatal flaccidity if used near delivery. Used routinely for cesarean sections.
Driving: Not applicable. Patients will be under general anesthesia and must not drive or operate machinery until fully recovered from anesthesia and neuromuscular blockade, which is typically many hours post-procedure.
| Inhalational Anesthetics (Isoflurane, Sevoflurane, Desflurane) | Potentiate neuromuscular blockade, reducing rocuronium requirement by 30-40% and prolonging duration. | Major |
| Aminoglycosides (Gentamicin, Tobramycin) | Potentiate neuromuscular blockade, potentially causing prolonged apnea. | Major |
| Magnesium Sulfate | Potentiates neuromuscular blockade. | Major |
| Calcium Channel Blockers (Verapamil, Diltiazem) | May enhance neuromuscular blocking effect. | Moderate |
| Lithium | May prolong neuromuscular blockade. | Moderate |
| Phenytoin, Carbamazepine | May cause resistance to rocuronium, requiring higher doses. | Moderate |
| Sugammadex | Binds rocuronium with high affinity, providing rapid and complete reversal of neuromuscular blockade. | Therapeutic (Reversal) |
| Neostigmine / Pyridostigmine | Antagonizes neuromuscular blockade by increasing acetylcholine levels. | Therapeutic (Reversal) |
Same composition (Rocuronium (100mg)), different brands: